Kallmann’s Syndrome: A Rare Cause of Primary AmenorrhoeaSamsad Jahan1*, Shahana Shermin1, Samira Humaira Habib2 and Reefat Nayer1
- *Corresponding Author:
- Dr. Samsad Jahan
Consultant and Associate Professor
Department of Gynecology and Obstetrics
BIRDEM, Dhaka, 122 Kazi Nazrul Islam Avenue, Dhaka-1000, Bangladesh
Tel: 880 2 8616641-50/ext-2270
E-mail: [email protected]; [email protected]; [email protected]
Received date May 30, 2014; Accepted date September 22, 2014; Published date September 26, 2014
Citation: Jahan S, Shermin S, Habib SH, Nayer R (2014) Kallmann’s Syndrome: A Rare Cause of Primary Amenorrhoea. Gynecol Obstet (Sunnyvale) 4:250. doi: 10.4172/2161-0932.1000250
Copyright: © 2014 Jahan S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Kallmann syndrome is a very rare hereditary disease. It is characterized by hypogonadotropic hypogonadism in association with anosmia ot hyposmia, both of which occur as a result of impairment of olfactory axon development and failure of migration of gonadotropin-releasing hormone (GnRH) neurons. Mode of inheritance can be autosomal dominant, autosomal recessive, or X-linked. We report a case of Kallmann syndrome in an 18 year old girl who presented with primary amenorrhoea, poor sexual development with poor sense of smell and colour blindness. Plasma levels of LH, FSH and oestradiol were very low. The patient’s other pituitary hormone levels were normal. Chromosome analysis showed 46, XX karyotype. USG of lower abdomen confirmed presence of uterus and ovaries. MRI of brain showed olfactory bulbs to be present and there was no pituitary or hypothalamic lesion. We present this case for its very rare occurrence in the eastern part of the world and the typical feature being normal MRI brain with functional defect of the olfactory pathway. Treatment was started with cyclic conjugated oestrogen and progestin. Our patient is now on regular follow-up to monitor response to treatment.